Skip to main content

Anika Therapeutics Value Stock - Dividend - Research Selection

Anika therapeutics

ISIN: US0352551081 , WKN: 889120

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company\'s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Are Options Traders Betting on a Big Move in Anika Therapeutics (ANIK) Stock?

2025-04-03
Investors need to pay close attention to Anika Therapeutics (ANIK) stock based on the movements in the options market lately.

Anika Therapeutics Full Year 2024 Earnings: Misses Expectations

2025-03-14
Anika Therapeutics ( NASDAQ:ANIK ) Full Year 2024 Results Key Financial Results Revenue: US$119.9m (down 28% from FY...

Q4 2024 Anika Therapeutics Inc Earnings Call

2025-03-13
Q4 2024 Anika Therapeutics Inc Earnings Call

Anika Therapeutics Inc (ANIK) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges

2025-03-13
Despite a slight dip in annual revenue, Anika Therapeutics Inc (ANIK) showcases robust commercial channel growth and strategic advancements.

Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates

2025-03-12
Anika (ANIK) delivered earnings and revenue surprises of -133.33% and 2.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Anika: Q4 Earnings Snapshot

2025-03-12
BEDFORD, Mass. AP) — Anika Therapeutics Inc. ANIK) on Wednesday reported a loss of $21.9 million in its fourth quarter.

Anika Reports Fourth Quarter and Full Year 2024 Financial Results

2025-03-12
Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIR

Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript

2025-03-12
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ETCompany ParticipantsMatt Hall - Director, Corporate...

Anika Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation

2025-03-12

Anika Completes Divestiture of Parcus Medical

2025-03-07
Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions PortfolioBEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced the completion of the previously announced planned divestiture of its Parcus Medical business. Management Commentar